EU/3/16/1794: Orphan designation for the diagnosis of gastrointestinal stromal tumours



On 12 December 2016 orphan designation (EU/3/16/1794) was granted by the European Commission to Advanced Accelerator Applications, France, for 68Ga-DOTA-pABzA-DIG-dPhe-Gln-Trp-Ala-Val-Gly-His-NHCH[(CH2-CH(CH3)2]2 (also known as 68Ga-NeoBOMB1) for the diagnosis of gastrointestinal stromal tumours.

Key facts

Active substance
Intended use
Diagnosis of gastrointestinal stromal tumours
Orphan designation status
EU designation number
Date of designation

Advanced Accelerator Applications
8 Rue Henri Sainte Claire Deville
92500 Rueil-Malmaison

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

May 2023The sponsor’s address was updated.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating